101 related articles for article (PubMed ID: 2950266)
1. Role of administration route in the therapeutic efficacy of doxifluridine.
Trave F; Canobbio L; Au JL; Rustum YM
J Natl Cancer Inst; 1987 Mar; 78(3):527-32. PubMed ID: 2950266
[TBL] [Abstract][Full Text] [Related]
2. Metabolism and biological activity of 5'-deoxy-5-fluorouridine, a novel fluoropyrimidine.
Armstrong RD; Diasio RB
Cancer Res; 1980 Sep; 40(9):3333-8. PubMed ID: 6253060
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and bioavailability of oral 5'-deoxy-5-fluorouridine in cancer patients.
Van Der Heyden SA; Highley MS; De Bruijn EA; Tjaden UR; Reeuwijk HJ; Van Slooten H; Van Oosterom AT; Maes RA
Br J Clin Pharmacol; 1999 Apr; 47(4):351-6. PubMed ID: 10233196
[TBL] [Abstract][Full Text] [Related]
4. Increased cytotoxicity of 5'-deoxy-5-fluorouridine by prolonged culture with folinic acid.
Matsuoka H; Furusawa M; Tomoda H; Seo Y; Sugimachi K
Anticancer Res; 1993; 13(6A):2201-6. PubMed ID: 8297134
[TBL] [Abstract][Full Text] [Related]
5. Pharmacology of 5'-deoxy-5-fluorouridine in patients with resistant ovarian cancer.
de Bruijn EA; van Oosterom AT; Tjaden UR; Reeuwijk HJ; Pinedo HM
Cancer Res; 1985 Nov; 45(11 Pt 2):5931-5. PubMed ID: 2932219
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic efficacy of fluoropyrimidines depends on the duration of thymidylate synthase inhibition in the murine colon 26-B carcinoma tumor model.
van Laar JA; van der Wilt CL; Rustum YM; Noordhuis P; Smid K; Pinedo HM; Peters GJ
Clin Cancer Res; 1996 Aug; 2(8):1327-33. PubMed ID: 9816304
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of the weekly intravenous push schedule of 5-fluoro-2'-deoxyuridine +/- N-phosphonacetyl-L-aspartate in mice bearing advanced colon carcinoma 26.
van Laar JA; Durrani FA; Rustum YM
Cancer Res; 1993 Apr; 53(7):1560-4. PubMed ID: 8453623
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic studies of 5-fluorouracil and 5'-deoxy-5-fluorouridine in rats.
Au JL; Walker JS; Rustum Y
J Pharmacol Exp Ther; 1983 Oct; 227(1):174-80. PubMed ID: 6225866
[TBL] [Abstract][Full Text] [Related]
9. Kinetics and metabolism of a new fluoropyrimidine, 5'-deoxy-5-fluorouridine, in humans.
Sommadossi JP; Aubert C; Cano JP; Gouveia J; Ribaud P; Mathé G
Cancer Res; 1983 Feb; 43(2):930-3. PubMed ID: 6216947
[TBL] [Abstract][Full Text] [Related]
10. Cytotoxic activity of 5'-deoxy-5-fluorouridine in cultured human tumors.
Armstrong RD; Gesmonde J; Wu T; Cadman E
Cancer Treat Rep; 1983 Jun; 67(6):541-5. PubMed ID: 6222789
[TBL] [Abstract][Full Text] [Related]
11. Precursor-dependent differences in the incorporation of fluorouracil in RNA.
Takimoto CH; Cadman EC; Armstrong RD
Mol Pharmacol; 1986 Jun; 29(6):637-42. PubMed ID: 2940459
[TBL] [Abstract][Full Text] [Related]
12. Selective activation of 5'-deoxy-5-fluorouridine by tumor cells as a basis for an improved therapeutic index.
Armstrong RD; Diasio RB
Cancer Res; 1981 Dec; 41(12 Pt 1):4891-4. PubMed ID: 6171343
[TBL] [Abstract][Full Text] [Related]
13. Biological activities of 5-fluorouracil and its prodrug 5'-deoxy-5-fluorouridine in rats.
Au JL; Rustum YM; Slocum HK
Cancer Drug Deliv; 1987; 4(3):137-44. PubMed ID: 2967103
[TBL] [Abstract][Full Text] [Related]
14. Remarkable antitumor activity of 5'-deoxy-5-fluorouridine in human colorectal tumor xenografts.
De Cesare M; Pratesi G; De Braud F; Zunino F; Stampino CG
Anticancer Res; 1994; 14(2A):549-54. PubMed ID: 8017859
[TBL] [Abstract][Full Text] [Related]
15. Schedule dependency of antitumor activity in combination therapy with capecitabine/5'-deoxy-5-fluorouridine and docetaxel in breast cancer models.
Fujimoto-Ouchi K; Tanaka Y; Tominaga T
Clin Cancer Res; 2001 Apr; 7(4):1079-86. PubMed ID: 11309360
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activities of a novel fluoropyrimidine, N4-pentyloxycarbonyl-5'-deoxy-5-fluorocytidine (capecitabine).
Ishikawa T; Fukase Y; Yamamoto T; Sekiguchi F; Ishitsuka H
Biol Pharm Bull; 1998 Jul; 21(7):713-7. PubMed ID: 9703255
[TBL] [Abstract][Full Text] [Related]
17. Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts.
Ishikawa T; Sekiguchi F; Fukase Y; Sawada N; Ishitsuka H
Cancer Res; 1998 Feb; 58(4):685-90. PubMed ID: 9485021
[TBL] [Abstract][Full Text] [Related]
18. Comparative studies on the antitumor and immunosuppressive effects of the new fluorouracil derivative N4-trimethoxybenzoyl-5'-deoxy-5-fluorocytidine and its parent drug 5'-deoxy-5-fluorouridine.
Miwa M; Ishikawa T; Eda H; Ryu M; Fujimoto K; Ninomiya Y; Umeda I; Yokose K; Ishitsuka H
Chem Pharm Bull (Tokyo); 1990 Apr; 38(4):998-1003. PubMed ID: 2143107
[TBL] [Abstract][Full Text] [Related]
19. Induction of thymidine phosphorylase expression and enhancement of efficacy of capecitabine or 5'-deoxy-5-fluorouridine by cyclophosphamide in mammary tumor models.
Endo M; Shinbori N; Fukase Y; Sawada N; Ishikawa T; Ishitsuka H; Tanaka Y
Int J Cancer; 1999 Sep; 83(1):127-34. PubMed ID: 10449619
[TBL] [Abstract][Full Text] [Related]
20. Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts.
Ishikawa T; Utoh M; Sawada N; Nishida M; Fukase Y; Sekiguchi F; Ishitsuka H
Biochem Pharmacol; 1998 Apr; 55(7):1091-7. PubMed ID: 9605432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
